|Bid||0.00 x 0|
|Ask||220.00 x 0|
|Day's range||204.00 - 209.00|
|52-week range||161.60 - 272.49|
|Beta (5Y monthly)||0.24|
|PE ratio (TTM)||N/A|
|Earnings date||11 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||20 Jun 2019|
|1y target est||271.00|
On Wednesday we chose a healthcare company as our stock tip of the year, on the basis not only of our expectations of its own recovery but because of investors’ recent aversion to the sector as a whole. We will double down on that belief today and pick our investment trust of the year from the same arena.
Gyroscope's parent company, London-listed healthcare investment firm Syncona Ltd, said on Wednesday that Novartis will pay $800 million upfront and up to $700 million in additional milestone payments. Gyroscope's treatment for geographic atrophy, a disease of the retina that leads to blindness and for which there is currently no treatment, is in the second phase of clinical development. Gene therapies are currently among the world's most expensive drugs.
Sitting in a tiny room in the bowels of the gigantic Wellcome Trust building in London, there must have been a brief moment when Martin Murphy questioned his life choices. It was 2012 and he had just left his comfortable career in venture capital to help the Wellcome Trust write the blueprint for a completely new type of company. “It was a handshake deal with Bill Castell, who was the chairman of Wellcome,” the 52-year-old recalls. “I turned up and it was me on my own in this little cupboard – w